Skip to main content
. 2022 Jul 26;12(8):1031. doi: 10.3390/biom12081031

Figure 1.

Figure 1

Timeline of the drug Dostarlimab since the demonstrated potential to treat a subset of women with EC to the reported 100% remission rate in rectal cancer.